Jonathan Serody, MD (IMAGE)
Caption
“We hope that these study results will lead to a clinical trial of chemotherapy with or without immunotherapy. We also hope to identify robust biomarkers of response to immunotherapy that can be incorporated into future study designs,” said Jonathan Serody, MD.
Credit
UNC Lineberger Comprehensive Cancer Center
Usage Restrictions
None
License
Original content